PT-141 (Bremelanotide) vs Setmelanotide

The distinction that mattersBoth melanocortin agonists. Setmelanotide targets MC4R for genetic obesity and is dosed daily; PT-141 targets MC3R/MC4R for sexual desire and is dosed on demand.

	PT-141 (Bremelanotide) FDA Approved	Setmelanotide FDA Approved
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong	5/5 Very strong Evidence rating 5 out of 5: Very strong
Regulatory status	FDA-approved (2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women	FDA-approved for obesity due to POMC, PCSK1 or LEPR deficiency, and for Bardet-Biedl syndrome
Category	Sexual Health & Melanocortin	Metabolic & Weight
Drug class	Melanocortin receptor agonist (MC3R/MC4R) — cyclic heptapeptide	Melanocortin-4 receptor (MC4R) agonist — cyclic octapeptide
Route	Subcutaneous autoinjector, as needed	Subcutaneous, once daily
Half-life	~2.7 hours	~11 hours
Sequence length	7 residues	8 residues
Molecular weight	1,025.2 Da	1,117.3 Da
Studied in	RECONNECT phase 3 trials in premenopausal women with HSDD; earlier studies in erectile dysfunction including an intranasal formulation that was discontinued over blood-pressure effects.	Pivotal open-label trials in POMC/LEPR deficiency and a randomized trial in Bardet-Biedl syndrome.
Who should avoid it	Uncontrolled hypertension Known cardiovascular disease Pregnancy Postmenopausal women and men (outside approved indication)	Patients without a qualifying genetic diagnosis Pregnancy Untreated significant depression (relative)
Legal status	Prescription drug for its labelled indication. "Research grade" PT-141 sold online is unapproved.	Prescription drug restricted to labelled genetic indications.

Benefits — PT-141 (Bremelanotide)

Statistically significant desire improvement
Phase 3 trials showed improvement in validated desire and distress scores versus placebo, sufficient for FDA approval.
On-demand rather than daily dosing
Taken ahead of anticipated activity, unlike flibanserin which requires continuous daily use.
Central mechanism
Addresses desire directly, useful where vascular-acting drugs are irrelevant to the problem.
No alcohol interaction restriction
A practical advantage over flibanserin, which carries alcohol warnings.

Benefits — Setmelanotide

Large weight loss in genetically defined obesity
Most patients with POMC or LEPR deficiency achieved 10% or greater weight loss at one year, in a population previously considered untreatable.
Marked hunger reduction
Patient-reported hyperphagia scores fell substantially, which for these families is often more meaningful than the weight number.
Clear genetic selection criteria
Confirmatory genetic testing identifies responders before treatment, avoiding open-ended trials of therapy.

Risks & cons — PT-141 (Bremelanotide)

Nausea
The dominant adverse effect — roughly 40% of patients in trials, and about 1 in 8 required an antiemetic.
Transient blood pressure increase
Systolic rises of several mmHg with a compensatory heart-rate decrease. Contraindicated in uncontrolled hypertension or known cardiovascular disease.
Hyperpigmentation with repeated dosing
Focal darkening of the face, gums and breasts occurred in trials, more often with frequent use; may be permanent. Dosing is capped at 8 doses per month partly for this reason.
Modest average effect size
Statistically significant but clinically modest; response rates leave many patients unimproved.
Flushing and injection-site reactions
Common but generally mild.

Risks & cons — Setmelanotide

Skin hyperpigmentation
Very common, because MC1R cross-activation increases melanin. New or darkening naevi need dermatologic assessment.
Depression and suicidal ideation warning
Labelled warning requiring psychiatric monitoring, particularly in adolescents.
Spontaneous penile erections
A predictable melanocortin class effect; reported in a substantial minority of male patients.
Injection-site reactions and nausea
Common but usually manageable.
No benefit in common polygenic obesity
It is not a general weight-loss drug and should not be sought as one.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.